Semax regulatory status: Category 2 and the reclassification path
Semax left FDA Category 2 in April 2026 — but removal isn't approval to compound.
Update, September 14, 2026: FDA's Pharmacy Compounding Advisory Committee met on July 24, 2026, and voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. FDA has not made a final decision.
TL;DR
- Semax's regulatory status changed in April 2026 — the FDA removed it from Category 2.
- Removal isn't approval. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list.
- At its July 24, 2026 meeting, the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding Semax to the 503A bulks list. FDA has not made a final decision.
Semax regulatory status: removed from Category 2, still short of compounding approval
Semax is a synthetic peptide (in plain English: a lab-made chain of amino acids, protein's building blocks). It comes from adrenocorticotropic hormone, or ACTH (in plain English: a stress hormone your pituitary gland releases). Developed in Russia, Semax has never been approved by the U.S. Food and Drug Administration (FDA) (Eremin et al., Neurochemical Research, 2005). In late 2023, the FDA flagged Semax and 18 other peptides as Category 2 under Section 503A (in plain English: the FDA rule for custom-mixed pharmacy medicines) — a safety-risk flag. On April 22, 2026, FDA removed Semax and 11 other peptides from Category 2 after their nominations were withdrawn (FDA, 2026).
How Semax's Category 2 removal and PCAC review fit together
Think of FDA compounding approval as two checkpoints. The first is Category placement, a safety-risk screen; FDA removed Semax from Category 2 on April 22, 2026. The second is a recommendation from the Pharmacy Compounding Advisory Committee (PCAC — in plain English: the expert panel that votes on which substances pharmacies may compound). The PCAC met on July 24, 2026 (FDA, 2026), and voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Clearing Category 2 opened a door; Semax hasn't walked through it yet.
Who asks about Semax's regulatory status
People ask after reading that Semax "isn't Category 2 anymore" and wondering if that makes it legal to buy compounded. Others are tracking the broader reclassification wave and want to know where things stand.
What the research says about Semax and its path to compounding
Semax's underlying science and its regulatory status are separate tracks. Published research comes mostly from animal studies in Russia, linking Semax to dopamine and serotonin activity in the brain (Eremin et al., Neurochemical Research, 2005). Semax was removed from Category 2 alongside TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, and PEG-MGF (FDA, 2026).
What to know before considering Semax's regulatory status
Semax isn't available from a licensed U.S. pharmacy, and that won't change automatically. At its July 24, 2026 meeting, the PCAC voted to recommend adding Semax to the 503A bulks list. The committee is advisory, and FDA has not made a final decision as of September 14, 2026. Even if Semax clears review, compounded Semax still won't be FDA-approved — 503A pharmacies compound from bulk substances, not approved products. Anyone considering Semax should wait for a licensed physician and a confirmed pathway.
The Halftime POV
We'd rather explain what changed than let a "removed from Category 2" headline do the work. That distinction — cleared one review, not yet cleared for compounding — is the whole story. We'll update this page when FDA acts on the PCAC vote.
Related reading:
- PCAC advisory committee, explained
- Why some peptides are still stuck in Category 2
- PCAC July 2026 meeting: what's on the agenda
- Reading the FDA's PCAC briefing documents
- The second PCAC meeting: five more peptides under review for 2027
FAQ
Q: Is Semax legal in the US? A: Semax is not FDA-approved. FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. FDA's policy of not acting against compounding with a substance that is not yet on the 503A bulks list applies only to substances in Category 1, when other conditions are met. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Q: What does removal from Category 2 mean for Semax? A: It means Semax's nomination was withdrawn, and FDA removed Semax from its Category 2 list on April 22, 2026. FDA says it is evaluating these substances at its discretion. Removal does not mean Semax was added to the 503A bulks list. As of September 14, 2026, Semax is not on that list. The Pharmacy Compounding Advisory Committee voted to recommend Semax in July 2026, and FDA has not made a final decision.
Q: When will Semax be reclassified? A: At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Q: Is Semax FDA approved? A: No. Semax has never been approved by the FDA for any use in the United States. Even if it eventually clears compounding review, compounded Semax would still not itself be an FDA-approved drug product.
Q: What did the Pharmacy Compounding Advisory Committee review the week of July 23, 2026? A: On July 23, 2026, the committee reviewed BPC-157, KPV, TB-500, and MOTS-c. On July 24, 2026, it reviewed Emideltide (DSIP), Semax, and Epitalon. It voted to recommend all of them except Emideltide (DSIP).
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA
- Eremin KO et al., "Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents," Neurochemical Research (2005)
Frequently asked questions
Is Semax legal in the US?
Semax is not FDA-approved. FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. FDA's policy of not acting against compounding with a substance that is not yet on the 503A bulks list applies only to substances in Category 1, when other conditions are met. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
What does removal from Category 2 mean for Semax?
It means Semax's nomination was withdrawn, and FDA removed Semax from its Category 2 list on April 22, 2026. FDA says it is evaluating these substances at its discretion. Removal does not mean Semax was added to the 503A bulks list. As of September 14, 2026, Semax is not on that list. The Pharmacy Compounding Advisory Committee voted to recommend Semax in July 2026, and FDA has not made a final decision.
When will Semax be reclassified?
At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Is Semax FDA approved?
No. Semax has never been approved by the FDA for any use in the United States. Even if it eventually clears compounding review, compounded Semax would still not itself be an FDA-approved drug product.
What did the Pharmacy Compounding Advisory Committee review the week of July 23, 2026?
On July 23, 2026, the committee reviewed BPC-157, KPV, TB-500, and MOTS-c. On July 24, 2026, it reviewed Emideltide (DSIP), Semax, and Epitalon. It voted to recommend all of them except Emideltide (DSIP).
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.